Supplementary Material “Genetics of the bitter taste receptor T2R38 underlie susceptibility to upper respiratory infection”
1
SUPPLEMENTARY MATERIAL
Supplementary Figure 1 Apical PTC application results in a dose-dependent elevation of [Ca2+]i in the majority of cells within sinonasal ALI cultures. (A) Representative F/Fo image showing PTC-induced increase in Fluo-4 fluorescence in all loaded cells (PAV/PAV culture) in the field of view (loading determined by ATP response, which should activate all cells), agreeing with immunofluorescence data showing ubiquitous T2R38 expression in sinonasal ALI cultures (Figure 1). (B) Dose response curve of PTC-induced Ca2+ response in PAV/AVI (heterozygous) cultures. Peak Fluo-4 fluorescence in these experiments was 1.12 ± 0.02 (1 mM PTC; n = 3 cultures), 1.20 ± 0.01 (7.5 mM PTC; n = 4 cultures), and 1.32 ± 0.05 (15 mM PTC; n = 7 cultures). (C) Apical, but not basolateral, application of PTC induced Ca2+ elevations. Shown is one representative trace from 4 experiments using PAV/PAV taster cultures. (D) Apical application of vehicle (DMSO) had no effect on Ca2+ either at the concentrations used (0.1%-0.5%) or higher (1%). Shown is 1 representative trace from 3 PAV/PAV cultures tested.
0.5
F/F
o
2 min
0.1 1
DMSO (%)
PTC
ATP
0.5
1.0
1.1
1.2
1.3
1.4
PAV/AVI + 1 mM PTC
PAV/AVI + 7.5 mM PTC
PAV/AVI + 15 mM PTC
1 min
PTC
Flu
o-4
F/F
o
B
Supplementary Figure 1
A
50 !m
Flu
o-4
F/F
o
1
8
0.5
F/F
o
2 minbasolateral PTC
apical PTC
apical ATP
C D
50 !m
Before PTC 3 min after 5 min after + ATP
Supplementary Material “Genetics of the bitter taste receptor T2R38 underlie susceptibility to upper respiratory infection”
2
Supplementary Figure 2 Differences between PAV/PAV and AVI/AVI cultures are not likely due to intrinsic defects in Ca2+ signaling or T2R38 expression. (A-B) Three concentrations of the purinergic agonist ATP were tested, applied apically to naïve cultures that had not been previously exposed to PTC. Shown are average traces from PAV/PAV (A) and AVI/AVI (B) cultures (n = 4 cultures from 4 pts of each genotype for each ATP concentration). No differences were observed in the magnitude or kinetics of the responses. (C). Bar graph showing peak Fluo-4 fluorescence during ATP stimulation. Fluo-4 fluorescence was 1.66 ± 0.09 (PAV/PAV taster) and 1.63 ± 0.08 (AVI/AVI nontaster) during 100 nM ATP stimulation, 2.78 ± 0.39 (PAV/PAV) and 2.80 ± 0.30 (AVI/AVI) during 1 µM ATP stimulation, and 3.64 ± 0.23 (PAV/PAV) and 3.26 ± 0.35 (AVI/AVI) during 10 µM ATP stimulation. As indicated, no values were significantly different between genotypes, determined by 2-tailed unpaired Student’s t-test. (D) Agarose gel (1.5%; 0.5 µg/ml EtBr stained) showing results from reverse transcription (rt) PCR of RNA isolated from ALI cultures. Expression of T2R38 and GAPDH (control) mRNA were both observed (766 and 502 bp, respectively). Primer sequences for human T2R38 were (forward) 5’-ACAGTGATTGTGTGCTGCTG-3’ and (reverse) 5’-GCTCTCCTCAACTTGGCATT-3’; primer sequences for GAPDH were (forward) 5’-ATCTTCCAGGAGCGAGATCC-3’ and (reverse) 5’-ACCACTGACACGTTGGCAGT-3’. (E) Representative immunofluorescence images of PAV/PAV and AVI/AVI cultures showing similar expression patterns and fluorescence intensity levels between the two genotypes.
Supplementary Figure 2
0.5
F/F o
1 min
100 nM ATP
100 nM ATP
0.5
F/F o
1 min
1 !M ATP
1 !M ATP
10 !M ATP
10 !M ATP
0.1 1 101
2
3
4PAV/PAVAVI/AVI
n.s.
n.s.
n.s.
[ATP] (!M)
Peak
Flu
o-4
F/F o
A B C
D RT: + + +- - -AVI/AVI PAV/AVI PAV/PAV
T2R38 (766 bp)GAPDH (502 bp)
E PAV/PAV AVI/AVI
Supplementary Material “Genetics of the bitter taste receptor T2R38 underlie susceptibility to upper respiratory infection”
3
Supplementary Figure 3 PTC-induced Ca2+ responses involve PLC, IP3 receptor, and TRPM5 function. All experiments performed with PAV/PAV cultures. (A) In the absence of extracellular Ca2+ (0-Ca2+
o solution), 5 mM PTC induced transient Ca2+ elevations, suggesting PTC causes Ca2+ release from intracellular stores while sustained responses require Ca2+ influx. Representative trace from 4 cultures. (B) After 5 mM PTC in 0-Ca2+
o, subsequent stimulation with ionomycin and thapsigargin (10 µg/ml each) revealed depletion of intracellular Ca2+ stores; Fluo-4 fluorescence did not increase until Ca2+ was added back to the extracellular solution. Representative trace from 4 cultures. (C) Prior Ca2+ store depletion by stimulation with ATP in 0-Ca2+
o solution resulted in no subsequent PTC (5 mM)-induced response. Representative trace from 4 cultures. (D) PTC (7.5 mM)-induced Ca2+ responses were blocked by the PLCβ2 inhibitor U73122 (5 µM; 10 min apical-side pre-incubation) but not by the inactive U73343. Responses to ATP were unaffected by the U73122 concentration used. (E) The Xestospongin-B (IP3 receptor inhibitor; 20 µM; 20 min apical pre-incubation) blocked PTC-induced Ca2+ responses in 0-Ca2+
o solution, suggesting IP3 receptor function is required for PTC-induced Ca2+ release. Subsequent stimulation with ionomycin/thapsigargin in continued 0-Ca2+
o confirmed that intracellular Ca2+ stores were intact. Representative trace from 4 cultures. (F) Incubation with 80 µM triphenylphosphine oxide, a TRPM5 blocker (Ref. 1) (TPPO; black trace; average of 6 cultures) resulted in transient Ca2+ elevation in response to 1 mM PTC. Blue trace shows control (no TPPO) responses from 6 cultures from the same patients.
0.5
F/F
o
3 min
0-Ca2+o
1.2 mM Ca2+o
PTC
iono/thaps
0.5
F/F
o
5 min
PTC
iono/thaps
0-Ca2+o
+ 1 mM EGTA
+ 20 !M XeB
PTC
0-Ca2+o
1.2 mM Ca2+o
1 min
0.2
F/F
o
PAV/PAV cultures
PTC
ATP
0.5
F/F
o
3 min
0-Ca2+o
1.2 mM Ca2+o
1.0
1.2
1.41.5
2.0
2.5
3.0 PAV/PAV + U73343
PAV/PAV + U73122
PTC
2 min
Flu
o-4
F/F
o
D
A
C
E
B
PAV/PAV + TPPO
PAV/PAV control
0.1
F/F
o
2 min
PTC
F
Supplementary Figure 3
Supplementary Material “Genetics of the bitter taste receptor T2R38 underlie susceptibility to upper respiratory infection”
4
Supplementary Figure 4 C6HSL (200 µM) induces T2R38- and PLCβ2-dependent Ca2+ signals. (A) Average traces from 6 PAV/PAV cultures (2 each from 3 patients) , 6 AVI/AVI cultures (2 each from 3 patients), and 4 PAV/PAV cultures (1 each from 4 patients) treated with U73122. (B) Bar graph showing results from A. Average peak Fluo-4 F/Fo after 5 min stimulation with C6HSL was 1.52 ± 0.074 (PAV/PAV), 1.10 ± 0.09 (PAV/PAV + U73122; P <0.05 vs PAV/PAV), and 1.21 ± 0.09 (AVI/AVI; P <0.05 vs PAV/PAV). Peak Fluo-4 F/Fo during 10 µM ATP stimulation was 2.96 ± 0.08 (PAV/PAV), 2.82 ± 0.1 (PAV/PAV + U73122; n.s. vs PAV/PAV), and 2.90 ± 0.09 (AVI/AVI; n.s. vs PAV/PAV). Significance derived from 1-way ANOVA with Tukey-Kramer post-test.
0.5
F/F
o
2 min
C6HSL
ATP
PAV/PAVAVI/AVI
PAV/PAV + U73122
C6HSL
1.0
1.2
1.4
1.6
1.82.5
3.0
3.5
Peak F
luo
-4 F
/Fo
PAV/PAV
PAV/PAV + U73122
C6HSL ATP
n.s.
p <0.05
AVI/AVI
A
B
Supplementary Figure 4
Supplementary Material “Genetics of the bitter taste receptor T2R38 underlie susceptibility to upper respiratory infection”
5
Supplementary Figure 5 Pseudomonas-conditioned medium (CM) and C6HSL activate PLCβ2-dependent Ca2+ responses. (A) Shown are average traces from 4 cultures from 4 taster patients for each condition. Cultures were either untreated or treated with 5 µM U73122 for 20 min before stimulation with filter sterilized PAO1 medium from a 3-day culture (diluted with PBS to the indicated concentration). No response was observed with LB alone. (B) In the absence of U73122, peak Fluo-4 F/Fo was 1.2 ± 0.04 (6.25% CM), 1.41 ± 0.12 (12.5% CM), and 1.86 ± 0.11 (25% CM). In the presence of U73122, peak Fluo-4 F/Fo was 1.05 ± 0.04 (6.25% CM) 1.09 ± 0.06 12.5% CM) and 1.2 ± 0.12 (25% CM). Significance is indicated in the bar graph and was determined by 2-tailed Student’s t-test; * = P <0.05 and ** = P <0.01.
Supplementary Figure 5
6.25%12.5%
25%
ATP
PAV/PAV + 3-Day CM
6.25% 12.5%25%
ATPPAV/PAV + CM + U73122
0.5
F/F
o
2 min
6.25% 12.5% 25%
ATP
LB only
6.25% 12.5% 25%1.0
1.2
1.4
1.6
1.8
2.0
Peak F
luo
-4 F
/Fo
PAV/PAV + CM
PAV/PAV + CM + U73122
*
*
**
A B
Supplementary Material “Genetics of the bitter taste receptor T2R38 underlie susceptibility to upper respiratory infection”
6
Supplementary Figure 6 Sequential addition experiments and siRNA knockdown experiments suggest that PTC and C4HSL activate Ca2+ signaling through a common T2R38-dependent pathway. (A) Addition of a high concentration of C4HSL (400 µM) after addition of a high concentration of PTC (15 mM) resulted in no further enhancement of Ca2+signaling. Likewise, addition of PTC after C4HSL had little effect on Ca2+ signaling. In either case, subsequent addition of 10 µM ATP, which acts through a purinergic receptor-dependent T2R-independent pathway, resulted in a further increase in Ca2+ concentration. Shown are average Fluo-4 traces from >80 cells in 1 culture, each ± SEM. (B) Three separate siRNA duplexes directed against different regions of the Tas2R38 mRNA sequence inhibited Ca2+ elevations in response to C4HSL (left) and C12HSL (right; n = 4 cultures from 2 patients for each condition). Responses to C4HSL and C12HSL in cells transfected with control RNA are reproduced on each graph for each agonist. Purinergic receptor-dependent Ca2+ responses were unaffected. (C) Bar graph showing peak Ca2+ responses after 5 min stimulation with C4HSL (1.30 ± 0.02, control; 1.09 ± 0.05, siRNA 54; 1.11 ± 0.05, siRNA 55; 1.10 ± 0.01, siRNA 56; all siRNA values P <0.05 vs control), C12HSL (1.45 ± 0.05, control; 1.12 ± 0.05, siRNA 54; 1.13 ± 0.04, siRNA 55; 1.03 ± 0.05, siRNA 56; all siRNA values P <0.05 vs control), and ATP (2.42 ± 0.33, control; 2.47 ± 0.28, siRNA 54; 2.33 ± 0.32, siRNA 55; 2.46 ± 0.35, siRNA 56; all values n.s.).
PAV / PAV + control RNAPAV / PAV + siRNA 54
0.5
F/F o
2 min
C4HSL
ATP
C4HSL
ATP
PTC
PAV/AVIPTC
ATP
C4HSL
C4HSL
ATPPTC
5 min
0.5
F/F o
PTC
ATPC4HSL
Supplementary Figure 6
A
B
PAV / PAV + control RNA
0.5
F/F o
2 min
C4HSL
ATP
PAV / PAV + siRNA 55
PAV / PAV + control RNA
0.5
F/F o
2 min
C4HSL
ATP
PAV / PAV + siRNA 56
PAV / PAV + control RNAPAV / PAV + siRNA 54
0.5
F/F o
2 min
C12HSL
ATP
PAV / PAV + control RNA
0.5
F/F o
2 min
C12HSL
ATP
PAV / PAV + siRNA 55
PAV / PAV + control RNA
0.5
F/F o
2 min
C12HSL
ATP
PAV / PAV + siRNA 56
5 min C
4HSL
5 min C
12HSL
ATP
1.0
1.2
1.4
1.6
2.02.53.0
PAV / PAV + control RNAPAV / PAV + siRNA 54
**
n.s.
PAV / PAV + siRNA 55PAV / PAV + siRNA 56
Peak
Flu
o-4
F/F oC
Supplementary Material “Genetics of the bitter taste receptor T2R38 underlie susceptibility to upper respiratory infection”
7
Supplementary Figure 7 Ca2+ responses to PTC (1 mM) and C4HSL (200 µM) in acutely dissociated nasal ciliated epithelial cells. (A-E) After tissue was treated with protease for cell isolation, as small aliquot was washed and plated on glass coverslips coated with Bovine Type I collagen and human fibronectin. Cells were incubated in culture medium for 12-36 hrs to allow for cell adhesion. Cells were then washed 3 times with HBSS and loaded with Fluo-4 (10 µM Fluo-4AM for 10-15 min). Single adherent ciliated cells were then identified under differential interference contrast (40x; 0.8 NA UPlanFLN objective) and imaged as described in the methods. (A-C) Responses to PTC were observed in at least 3 dissociated ciliated cells from 3 different patients who were subsequently genotyped for TAS2R38 (brown traces are from PAV/AVI cultures; blue traces are from PAV/PAV cultures). (D-E) Responses to C4HSL were likewise observed in ciliated cells from the same patients. Scales of all traces in A-F are identical.
C4HSL ATP
1 F
/Fo
2 min
PTC ATP
C4HSLATP
C4HSL
ATP
PTC ATP
C4HSL ATP
C4HSL
ATP
PTCATP
PTC
ATP
PTCATP
PTC ATP
PTC ATP
PTC ATP
C4HSL ATP
C4HSL ATP
PTC
ATP
C4HSL
ATP
C4HSL
ATP
A B C
D E F
Supplementary Figure 7
Supplementary Material “Genetics of the bitter taste receptor T2R38 underlie susceptibility to upper respiratory infection”
8
Supplementary Figure 8 T2R38 does not activate β-defensin or cytokine secretion. (A) Apical surface of ALI cultures were washed with PBS; afterward, 30 µL of PBS or PBS + 1mM PTC or 100µM each C4HSL and C12HSL. ASL was harvested after 60 min or 14 hrs at 37°C. Basal β-defensin secretion occurred over 14 hrs, but no significant differences were observed between stimulated and unstimulated or PAV/PAV (blue bars) and AVI/AVI (red bars) cultures. (B) PAV/PAV cultures were incubated in the presence of PBS or PBS + 0.1 or 1 mM PTC or 0.1 mM C4HSL on the apical side. Basolateral media was serum-free BEBM/DMEM. Samples of basolateral media were taken at 30 min and 12 hr time-points to assay for IL-8 secretion. While basal secretion occurred over 12 hrs, no significant differences were observed between stimulated and unstimulated or PAV/PAV and AVI/AVI cultures. (C) Secretion of 18 cytokines was measured via Luminex multiplex assay from media as in B. No significant increase in any cytokine was observed upon stimulation with 1 mM PTC, 100 µM C4HSL, or 100 µM C12HSL. FLS-1 stimulated significant elevation of G-CSF, GM-CSF, IL-6, IL-8, IL-9, MCP1, MIP1α, MIP1β, TNFα, Eotaxin 3, and GROα. Pseudomonas LPS stimulated significant elevation of IL-6, IL-8, IL-9, and GROα. None of these values were significantly different between PAV/PAV or AVI/AVI cultures (4 cultures each from 4 patients). Asterisks represent significance compared with isogenic PBS condition; *P <0.05, **P <0.01 (ANOVA; Tukey-Kramer post-test).
0
50
100
150
!-d
efe
ns
in (
pg
/ml)
PBS PTC C4+12 PBS PTC C4+12
60 min 14 hrs
Eo
taxin
2 (p
g/m
l)
PBS
FSL1
LPS
PTC
C4H
SL
C12
HSL
0
20
40
60
80
100Taster
Nontaster
G-C
SF
(p
g/m
l)
PBS
FSL1
LPS
PTC
C4H
SL
C12
HSL
0
20
40
60
80
****
PBS
FSL1
LPS
PTC
C4H
SL
C12
HSL
0
1000
2000
3000
4000
GR
O"
(p
g/m
l)
***
**
PBS
FSL1
LPS
PTC
C4H
SL
C12
HSL
0
10
20
30
Eo
taxin
3 (p
g/m
l) **
GM
-CF
S (p
g/m
l)
PBS
FSL1
LPS
PTC
C4H
SL
C12
HSL
0
10
20
30*
*
IFN#
(pg
/ml)
PBS
FSL1
LPS
PTC
C4H
SL
C12
HSL
0
2
4
6
8
PBS
FSL1
LPS
PTC
C4H
SL
C12
HSL
0.0
0.5
1.0
1.5
2.0IL
-17F
(p
g/m
l)
IL-1
0 (p
g/m
l)
PBS
FSL1
LPS
PTC
C4H
SL
C12
HSL
0
2
4
6
PBS
FSL1
LPS
PTC
C4H
SL
C12
HSL
0
2
4
6
8
IL-1"
(p
g/m
l)
PBS
FSL1
LPS
PTC
C4H
SL
C12
HSL
0
1
2
3
IL-1! (p
g/m
l)M
IP1"
(p
g/m
l)
PBS
FSL1
LPS
PTC
C4H
SL
C12
HSL
0
10
20
30
*
**
PBS
FSL1
LPS
PTC
C4H
SL
C12
HSL
0
10
20
30
40
MIP
1! (p
g/m
l)
*
**
PBS
FSL1
LPS
PTC
C4H
SL
C12
HSL
0
10
20
IL-6
(p
g/m
l)
*
****
*
PBS
FSL1
LPS
PTC
C4H
SL
C12
HSL
0
1000
2000
3000
IL-8
(p
g/m
l)
**
**
**
PBS
FSL1
LPS
PTC
C4H
SL
C12
HSL
0
100
200
300
IL-9
(p
g/m
l)
***
PBS
FSL1
LPS
PTC
C4H
SL
C12
HSL
0
1
2
3
4
5
IL-2
3/p
19 (p
g/m
l)
PBS
FSL1
LPS
PTC
C4H
SL
C12
HSL
0
10
20
30
40
50
MC
P1 (p
g/m
l) ***
PBS
FSL1
LPS
PTC
C4H
SL
C12
HSL
0
5
10
15
TN
F"
(p
g/m
l) ***
0
5
10
15
20
100
150
200
IL8
co
nc
en
tra
ito
n (
pg
/ml)
0.1PTC
1PTC
0.1C4
1PTC
0.1C4
PBS PBS
n.s.
n.s.
30 min 12 hr
B
B
Supplementary Figure 8
A
Supplementary Material “Genetics of the bitter taste receptor T2R38 underlie susceptibility to upper respiratory infection”
9
Supplementary Figure 9 NO-production during sustained intracellular Ca2+ elevation is independent of the TAS2R38 genotype. (A-B) Average traces of DAF-FM fluorescence in PAV/PAV and AVI/AVI cultures (4 each from 2 patients per genotype) treated with ionomycin and thapsigargin (10 µg/ml each; effective concentrations in these cultures based on Supplementary Figure 3) in the presence of extracellular Ca2+ to stimulate global, receptor independent, sustained Ca2+ elevation. (C) Pretreatment of PAV/PAV cultures with L-NAME blocked the response to ionomycin + thapsigargin. (D) Summary of data from a-c, showing net DAF-FM fluorescence increase over baseline at 1, 2 and 4 min after application of ionomycin + thapsigargin. DAF-FM fluorescence increase was 333 ± 82 (PAV/PAV), 316 ± 70 (AVI/AVI; n.s. vs PAV/PAV), and 41 ± 23 (PAV/PAV + L-NAME; P <0.01 vs PAV/PAV control) at 1 min, 475 ± 128 (PAV/PAV), 444 ± 112 (AVI/AVI; n.s. vs PAV/PAV), 56 ± 28 (PAV/PAV + L-NAME; P <0.01 vs PAV/PAV control) at 2 min, and 575 ± 155 (PAV/PAV), 540 ± 140 (AVI/AVI; n.s. vs PAV/PAV), and 70 ± 31 (PAV/PAV + L-NAME; P <0.01 vs PAV/PAV control). ** P <0.01 by ANOVA with Tukey-Kramer post-test.
1 min 2 min 4 min0
200
400
600
800
PAV/PAV
AVI/AVI
PAV/PAV + L-NAME
n.s.
n.s.
n.s.
**
**
**
DA
F-F
M
flu
ore
sc
en
ce
in
cre
as
e
PAV/PAV
20
0 u
nits
1 min
ionomycin +thapsigargin AVI/AVI
20
0 u
nits
1 min
ionomycin +thapsigargin
PAV/PAV + L-NAME
20
0 u
nits
1 min
ionomycin +thapsigargin
A B
C
Supplementary Figure 9
D
Supplementary Material “Genetics of the bitter taste receptor T2R38 underlie susceptibility to upper respiratory infection”
10
Supplementary Figure 10 PTC-induced NO generation is blocked by inhibitors of PLCβ2-dependent Ca2+ signaling. (A-B) Average DAF-FM traces (n = 4-7 cultures; 4 PAV/AVI pts for each condition) of cultures stimulated with 1 mM PTC in the presence of U73122 (PLCβ2 inhibibitor; blue trace; A) or U73343 (inactive analogue; brown trace; A) or after loading with BAPTA-AM in the presence of 1 mM EGTA (red trace; B). (C) Bar graph of data from A and B. After stimulation with 1 mM PTC, DAF-FM fluorescence increases were 89 ± 9 (U73343) vs 31 ± 12 (U73122; P <0.05 by ANOVA) vs 29 ± 9 (BAPTA/EGTA; P <0.05 by ANOVA) after 5 min and 151 ± 11 (U73343) vs 50 ± 21 (U73122; P <0.01) vs 48 ± 10 (BAPTA/EGTA; P <0.01). No significant difference was observed after stimulation with 100 µM SNAP for 5 min; DAF-FM fluorescence increase was 332 ± 89 (U73343) vs 300 ± 49 (U73122) vs 286 ± 91 (BAPTA/EGTA).
PAV/AVI + U73343PAV/AVI + U73122
1 mM PTC
SNAP
5 min2
00
un
its
5 min
1 mM PTC
SNAP
20
0 u
nits
PAV/AVI + BAPTA/EGTA
0
100
200
300
400 U73343
U73122
5 min PTC
10 min PTC
5 min SNAP
***
n.s.
BAPTA/EGTA
NO
pro
du
ce
d
(DA
F-F
M flu
ore
sc
en
ce
un
its
)
A
B
C
Supplementary Figure 10
Supplementary Material “Genetics of the bitter taste receptor T2R38 underlie susceptibility to upper respiratory infection”
11
Supplementary Figure 11 The T2R38 agonist sodium thiocyanate (NaSCN) activates NO generation in sinonasal ALIs, whereas 2 non–T2R38-activating bitter agonists have no effect. (A) Representative traces (each from ~100 cells from a single ALI; SEM smaller than symbol size; representative of 6 experiments each) of DAF-FM response to NaSCN. (B) Bar graph showing NO production in tasters and non-tasters (n = 3 pts [2 cultures each] for each genotype). When averaged by patient, DAF-FM fluorescence increase after 5 min NaSCN was 202 ± 38 units (PAV/PAV) vs 61 ± 23 units (AVI/AVI; P = 0.016 by Student’s t-test; *P <0.05) (C) Representative traces showing Ca2+ responses to NaSCN and ATP in the presence (black) or absence (blue; control) of L-NAME (50 µM). (D) After stimulation with 5 mM NaSCN, F/Fo was increased to 1.33 ± 0.08 (control) and 1.24 ± 0.07 (+ L-NAME; n.s. by Student’s t-test). Peak F/Fo during stimulation with 1 µM ATP was 1.9 ± 0.21 (control) and 2.0 ± 0.26 (L-NAME; n.s. by Student’s t-test). L-NAME had no significant effect on Ca2+ signaling at the concentration used, thus L-NAME block of DAF-FM fluorescence increase likely reflects inhibition of NOS. (E-F) Neither the T2R10 and T2R14 specific agonist thujone (5 mM) nor the T2R4, T2R8, T2R10, T2R13, T2R39, T2R43, T2R46, and T2R47-specific agonist denatonium benzoate (10 mM) had any effect on NO production. Shown are 2 representative traces for each agonist from 2 cultures from different PAV/PAV patients (4 patients tested). (G) Ca2+ responses to denatonium but not thujone were observed in sinonasal ALI cultures. (H) As a control for thujone activity, Ca2+ responses to thujone were observed in human bronchial epithelial (HBE) cells.
0.5
F/F
o
2 min
thujone
ATP
0.5
F/F
o
2 min
denat.
ATP
NaSCN ATP1.0
1.5
2.0
PAV/PAV
PAV/PAV + L-NAME
n.s.
n.s.
Pe
ak
Flu
o-4
F/F
o
1 NaSCN
SNAP
5 NaSCN
10 NaSCN
PAV/PAV
0
100
200
300
PAV/PAV
AVI/AVI
5 min 5 mM NaSCN
*
NO
pro
du
ce
d
(DA
F-F
M flu
ore
sc
en
ce
un
its
)
SNAP
AVI/AVI
1 NaSCN
5 NaSCN
10 NaSCN
SNAP
5 minDA
F-F
M2
00
un
its
PAV/PAV + L-NAME
5 NaSCN
10 NaSCN
A B
thujone PTC
SNAP
DA
F-F
M2
00
un
its
5 min
thujone PTC
SNAP
denat. PTC
SNAP
DA
F-F
M2
00
un
its
5 min
denat. PTC
SNAPE F
PAV/PAV
NaSCN
ATP
PAV/PAV+ L-NAME
NaSCN
ATP
2 min
Flu
o-4
0.5
F/F
o
C D
Supplementary Figure 11
1 F
/Fo
2 min
thujone
ATP
G H
Supplementary Material “Genetics of the bitter taste receptor T2R38 underlie susceptibility to upper respiratory infection”
12
Supplementary Figure 12 C4HSL-induced NO production is blocked by PLCβ2 and NOS inhibition as well as siRNA knockdown of Tas2R38 expression. (A) Average DAF-FM traces (left; 6 cultures from 3 PAV/PAV pts for each condition) stimulated with 200 µM C4HSL in the presence of U73122 or U73343 (5 µM each). (B) Bar graph of data from A averaged by patient (n = 3 each). After 5 min stimulation with C4HSL, DAF-FM fluorescence increase was 323 ± 10 (U73343) vs 29 ± 4 (U73122) units (P <0.001). After 10 min, fluorescence increase was 336 ± 10 (U73343) vs 56 ± 8 (U73122) units (P <0.01). No significant difference was observed after stimulation with SNAP (420 ± 32 and 487 ± 62 in U73343 and U73122-treated cultures, respectively). (C) Average DAF-FM traces (left; 6-10 cultures; 3 pts each) with C4HSL. (D) Results from C averaged by patient. Fluorescence increases with C4HSL were 183±43 (PAV/PAV), 99±1 (AVI/AVI), and 25±4 (PAV/PAV + L-NAME) after 5 min and 210±12 (PAV/PAV), 100±10 (AVI/AVI), and 33±7 (PAV/PAV + L-NAME) after 10 min. Increases after SNAP were not significantly different. (E-F) NO production in response to C4HSL (E) and C12HSL (F) was inhibited by siRNAs targeted against Tas2R38 expression (n = 4 cultures from 2 patients for each condition). Responses observed in cultures transfected with control RNA were reproduced for each graph in E and F. NO production in response to SNAP application was not different between control and siRNA transfected cultures. (G) Bar graph showing DAF-FM fluorescence increases after 5 min stimulation with C4HSL (141 ± 16, control; 54 ± 9, siRNA 54; 38 ± 7.5, siRNA 55; 55 ± 14, siRNA 56; all siRNA values P <0.05 vs control) or C12HSL (194 ± 32, control; 70 ± 15, siRNA 54; 35 ± 5, siRNA 55; 35 ± 14, siRNA 56; all siRNA values P <0.05 vs control) or 3 min stimulation with SNAP (199 ± 60, control; 176 ± 30, siRNA 54, 169 ± 13, siRNA 55; 165 ± 36; siRNA 56; all values n.s.).
PAV/PAVAVI/AVIPAV/PAV + L-NAME
5 min
C4HSL
SNAP
200
units
0
100
200
5 min C4HSL
10 min C4HSL
** ******
NO
pro
duce
d (D
AF-
FM fl
uor.
units
)
0
200
400
600
PAV/PAV + U73343
PAV/PAV + U73122
5 minC4HSL
10 min C4HSL
5 min SNAP
n.s.
** **
NO
pro
duce
d (D
AF-
FM fl
uor.
units
)
PAV/PAV + U73122PAV/PAV + U73343
5 min
C4HSL
SNAP
200
units
A B
Supplementary Figure 12
C D
0
100
200
300
3 min SNAP
PAV/PAV + L-NAMEAVI/AVIPAV/PAV
n.s.
PAV / PAV + control RNAPAV / PAV + siRNA 54
2 min200
units
C4HSL
SNAP
PAV / PAV + control RNA
2 min
200
units
C4HSL
SNAP
PAV / PAV + siRNA 55PAV / PAV + control RNA
2 min
200
units
C4HSL
SNAP
PAV / PAV + siRNA 56
PAV / PAV + control RNAPAV / PAV + siRNA 54
2 min
200
units
C12HSL
SNAPPAV / PAV + control RNA
2 min
200
units
C12HSL
SNAP
PAV / PAV + siRNA 55PAV / PAV + control RNA
2 min
200
units
C12HSL
SNAP
PAV / PAV + siRNA 56
E
G
5 min C
4HSL
5 min C
12HSL
3 min SNAP
0
50
100
150
200
250
** n.s.
PAV / PAV + control RNAPAV / PAV + siRNA 54N
O p
rodu
ced
(DA
F-FM
fluo
r. un
its)
PAV / PAV + siRNA 55PAV / PAV + siRNA 56
F
Supplementary Material “Genetics of the bitter taste receptor T2R38 underlie susceptibility to upper respiratory infection”
13
Supplementary Figure 13 Dilute (6.25%) Pseudomonas-conditioned-medium activates T2R38-dependent NO production (A) Average DAF-FM traces (9 cultures from 3 pts for each condition) stimulated with 6.25% Pseudomonas (3-day)-conditioned medium (CM) or LB (control). (B) Bar graph of results from C averaged by patient (n = 3 each). After 5 min stimulation with CM, DAF-FM fluorescence increase was 188 ± 12 units (PAV/PAV) and 90 ± 9 units (AVI/AVI; P <0.01); after stimulation with LB, DAF-FM fluorescence increased by 22 ± 7 units (PAV/PAV; P <0.01 PAV/PAV with CM). No significant difference was observed when cultures were stimulated with 100 µM SNAP. DAF-FM fluorescence increase was 443 ± 40 (PAV/PAV after CM), 388 ± 20 (AVI/AVI after CM), and 362 ± 48 (PAV/PAV after LB). (C) Conditioned media from PAO-JP2 as well as the TLR agonists LPS and FSL-1 did not stimulate NO * = P <0.05, and ** = P <0.01.
PAV/PAV + PAO1 CMAVI/AVI + PAO1 CMPAV/PAV + LB
3 min
20
0 u
nits
6.25%LB or CM
SNAP
A
0
50
100
150
200
250
**
5 min LB or PAO1 CM
NO
pro
du
ce
d
(DA
F-F
M f
luo
r. u
nit
s)B
0
100
200
300
400
500
PAV/PAV + CM
AVI/AVI + CM
PAV/PAV + LB
3 min SNAP
n.s.
Supplementary Figure 13
DA
F-F
M100 u
nit
s
2 min
6.25%PAO-JP2 SNAP
DA
F-F
M100 u
nit
s
2 min
FSL-1SNAP
DA
F-F
M100 u
nit
s
2 min
LPSSNAP
C DN
O p
rod
uc
ed
(D
AF
-FM
flu
or.
un
its
)
PAO1
CM
FSL1LPS
PAO-J
P2
CM
0
50
100
150
200
250
**
Supplementary Material “Genetics of the bitter taste receptor T2R38 underlie susceptibility to upper respiratory infection”
14
Supplementary Figure 14 Traces of T2R38-induced NO production in acutely dissociated ciliated epithelial cells. (A-J) Cells were isolated from nasal polyps removed from 2 patients (both PAV/AVI patients). DAF-FM was loaded by 15 min incubation with 10 µM DAF-FM diacetate in HBSS containing 20 µM cPTIO. After 4 washes with HBSS (no cPTIO), cells were imaged and DAF-FM fluorescence was recorded. (A-F) DAF-FM fluorescence was observed to increase in response to PTC (5 mM; A and B), NaSCN (5 mM; C and D), acetylthiourea (ATU, 2 mM; E and F). All three T2R38 agonists activated NO production. SNAP was included at the end as a positive control for dye loading. (G-H) C4HSL (100 µM) likewise induced an increase in DAF-FM fluorescence reflecting NO production. (I-J) PTC-induced, but not SNAP-induced DAF-FM fluorescence increases were blocked by L-NAME, demonstrating that the DAF-FM fluorescence increases specifically reflect NOS-mediated NO production in dissociated ciliated cells. Together, these data suggest that responses observed in sinonasal cultures recapitulate the responses of ciliated epithelial cells in vivo.
PTC SNAP
+ 20 !M L-NAME
PTCSNAP
ATU
SNAPATU
SNAP
ATU
SNAP
ATU
SNAP
20
0 u
nits
2 min
PTC
SNAP
PTC
SNAP
PTC
SNAP
NaSCN
SNAP
NaSCN
SNAP
NaSCN
SNAP
NaSCN
SNAP
NaSCN
SNAP
NaSCN
SNAP
C4HSL
SNAP
C4HSL
SNAP
C4HSL
SNAP
PTC
SNAP
PTC
SNAP
PTC
SNAP
PTCSNAP
+ 20 !M L-NAME
PTC SNAP
C4HSL
SNAP
C4HSL
SNAP
A B
HE F
C
G
C4HSL
SNAP
I J
D
Supplementary Figure 14
Supplementary Material “Genetics of the bitter taste receptor T2R38 underlie susceptibility to upper respiratory infection”
15
Supplementary Figure 15 No intrinsic differences in baseline and ATP-stimulated CBF were observed in AVI/AVI and PAV/PAV cultures. (A-D) Representative traces of raw (A-B) and normalized (C-D) CBF showing baseline and 1 µM ATP-stimulated CBF in PAV/PAV (A,C) and AVI/AVI (B,D) cultures. (E) Bar graph showing raw baseline and ATP-stimulated CBF averaged by patient (n = 2 cultures each from 4 patients for each genotype). Baseline CBF was 7.7 ± 1.4 Hz and 7.2 ± 0.2 Hz in PAV/PAV and AVI/AVI cultures, respectively (n.s. by Student’s t-test). CBF after stimulation with 1 µM ATP was 10.7 ± 1.3 Hz and 10.1 ± 0.3 Hz in PAV/PAV and AVI/AVI cultures, respectively (n.s. by Student’s t-test). (F) Bar graph showing normalized mean ATP-stimulated increase in CBF, which was 1.5 ± 0.09 and 1.4 ± 0.01 in PAV/PAV and AVI/AVI cultures, respectively (n.s. by Student’s t-test). (G). Bar graph showing raw resting CBF in untreated (control) PAV/PAV cultures as well as PAV/PAV cultures treated with the indicated inhibitors. Resting CBF was 7.7 ± 1.4 Hz in control cultures, 6.1 ± 0.34 Hz in D-NAME treated cultures, 7.9 ± 1.3 Hz in L-NAME-treated cultures, 7.1 ± 0.77 in KT5823-treated cultures, 7.5 ± 0.90 Hz in LY83583-treated cultures, 6.0 ± 0.51 Hz in H8-treated cultures, 6.6 ± 1.5 Hz in U73122-treated cultures, and 5.5 ± 0.81 Hz in U73343-treated cultures.
PAV/PAV (c
ontrol)
+ D-N
AME
+ KT58
23
+ L-N
AME
+ LY8358
3+ H
8
+ U73
122
+ U73
343
0
5
10
Bas
elin
e C
BF
(Hz) all values n.s. vs control
6
8
10
12
CB
F (H
z)PAV/PAV (raw)
2 min
ATP
Baseli
ne
After 1
!M A
TP
6
8
10
12
CB
F (H
z)
PAV/PAVAVI/AVI
n.s.
n.s.
6
8
10
12
CB
F (H
z)
AVI/AVI (raw)
2 min
ATP
0.8
1.0
1.2
1.4
1.6
1.8
CB
F stim
/ C
BF b
asal
PAV/PAV (normalized)
2 min
ATP
0.8
1.0
1.2
1.4
1.6
1.8
CB
F stim
/ C
BF b
asal
AVI/AVI (normalized)
2 min
ATP
1.0
1.2
1.4
1.6
1.8Fo
ld in
crea
se in
CB
F(C
BF s
tim /
CB
F bas
al)
PAV/PAVAVI/AVI
n.s.
A B
C D
E F
G
Supplementary Figure 15
Supplementary Material “Genetics of the bitter taste receptor T2R38 underlie susceptibility to upper respiratory infection”
16
Supplementary Figure 16 Pseudomonas-conditioned medium-stimulated CBF is blocked by inhibition of PLCβ2 or NOS. (A) Average traces showing normalized CBF in PAV/PAV cultures stimulated with 6.25% Pseudomonas CM in the presence of U73122 or U73343 (6 cultures each from 3 patients each). Peak CBF was 1.14 ± 0.09 with U73122 vs 1.76 ± 0.2 with U73343 (P = 0.02 vs U73122 by Students’ t-test; P < 0.05 vs U73122 and n.s. vs untreated cultures [b-c] by ANOVA). (B) Trace showing inhibition of CM-induced CBF increase by the NOS inhibitor L-NAME but not its inactive analogue, D-NAME. Cultures were pretreated with L-NAME or D-NAME (50 µM applied to the apical side only) for 15 min before CBF was measured (n = 6 culture from 3 pts for L-NAME and 9 cultures from 3 pts for D-NAME). Peak CBF was 1.02 ± 0.02 in the presence of L-NAME and 1.67 ± 0.14 in the presence of D-NAME (P < 0.01 vs L-NAME by Student’s t-test). (C) Bar graph showing peak CM-activated CBF increase from experiments in A-B; *P <0.05 and **P <0.01.
U7334
3
U7312
2
D-NAME
L-NAME
1.0
1.2
1.4
1.6
1.8
2.0
CB
F stim
/ C
BF b
asal
***
1.0
1.5
2.0
2.5
PAV/PAV + U73122PAV/PAV + U73343
5 minC
BF s
tim /
CB
F bas
al 6.25% CM ATP
1.0
1.5
2.0
2.5
CB
F stim
/ C
BF b
asal
6.25% CM
ATP
5 min
PAV/PAV + L-NAMEPAV/PAV + D-NAME
A
B
C
Supplementary Figure 16
Supplementary Material “Genetics of the bitter taste receptor T2R38 underlie susceptibility to upper respiratory infection”
17
Supplementary Figure 17 Dilute conditioned medium (CM) from planktonic Pseudomonas cultures stimulates a HSL-dependent CBF increase. Eight cultures from 4 PAV/PAV patients and 6 cultures from 3 AVI/AVI patients were used for each condition. (A) PAO-1 conditioned medium elevated CBF by 1.15 ± 0.03 (PAV/PAV) vs 1.03 ± 0.01 (AVI/AVI) at 3.13%, 1.267 ± 0.04 (PAV/PAV; P <0.05) vs 1.092 ± 0.03 (AVI/AVI; P <0.01) at 6.25%, and 1.41 ± 0.05 (PAV/PAV) vs 1.14 ± 0.06 (AVI/AVI; P <0.05) at 12.5%. (B) PAO-JP2 medium elevated CBF by 1.01 ± 0.007 (PAV/PAV) vs 1.006 ± 0.005 (AVI/AVI; n.s.) at 3.13%, 1.04 ± 0.02 (PAV/PAV) 1.04±0.03 (AVI/AVI; n.s.) at 6.25%, and 1.16 ± 0.03 (PAV/PAV) and 1.12 ± 0.04 (AVI/AVI; n.s.) at 12.5%. (C) Sad36 medium elevated CBF by 1.21 ± 0.05 (PAV/PAV) vs 1.003 ± 0.003 (AVI/AVI; P <0.05) at 3.13%, 1.43 ± 0.06 (PAV/PAV) vs 1.03 ± 0.02 (AVI/AVI; P <0.01) at 6.25%, and 1.59 ± 0.07 (PAV/PAV) vs 1.09 ± 0.02 (AVI/AVI; P <0.01) at 12.5%.
1.0
1.2
1.4
1.6
1.8
PAV/PAVAVI/AVI
2 min
3.13%6.25%
12.5%
ATPPAO-JP2
(!lasI, !rhlI)CM
CB
F stim
/ C
BF b
asal
1.0
1.2
1.4
1.6
1.8
PAV/PAVAVI/AVI
2 min
3.13%
6.25%
12.5%
ATP
PAO1 CM
CB
F stim
/ C
BF b
asal
1.0
1.2
1.4
1.6
1.8
2.0
PAV/PAVAVI/AVI
2 min
3.13%
6.25%
12.5%Sad36 CM
ATP
CB
F stim
/ C
BF b
asal
Supplementary Figure 17
A
B
C
Supplementary Material “Genetics of the bitter taste receptor T2R38 underlie susceptibility to upper respiratory infection”
18
Supplementary Figure 18 Pseudomonas-conditioned PBS (CPBS) activates an HSL-dependent increase in CBF. (A-C) Average traces showing CBF response to CPBS that had been exposed to PAO1 Pseudomonas for 30 min (A), 2 hrs (B), and 6 hrs (C) showing marked T2R38-dependent CBF increase (n = 4-7 cultures from 3 patients for each condition for each genotype). Peak CBF increases were [30 min CPBS] 1.22 ± 0.06 (PAV/PAV) vs 1.04 ± 0.01 (AVI/AVI; P <0.05), (2 hrs CPBS) 1.32 ± 0.01 (PAV/PAV) vs 1.06 ± 0.02 (AVI/AVI; P <0.01), and [6 hrs CPBS] 1.43 ± 0.03 (PAV/PAV) vs 1.09 ± 0.02 (AVI/AVI; P <0.01). (D) Dialysis of 6 hrs CPBS using 3,500 MWCO dialysis membrane resulted in a complete loss of CBF stimulatory activity. Cell viability was confirmed with ATP stimulation. (E) Conditioned PBS exposed to approximately the same amount (OD 0.1) of HSL-deficient Pseudomonas PAO-JP2 did not stimulate an increase in CBF (n = 4 cultures from 4 patients per genotype). (F) CPBS (6 hrs) from the flagella mutant Sad36 exhibited a robust T2R38-dependent CBF increase (n = 3 cultures from 3 patients for each genotype). CBF increases were 1.30 ± 0.08 (PAV/PAV; n.s. vs PAO-1 CPBS PAV/PAV) and 1.07 ± 0.01 (AVI/AVI; P <0.01 vs Sad36 PAV/PAV).
1.0
1.2
1.4
1.6
PAV/PAVAVI/AVI
2 min
50% 30 min PAO1
CPBS
ATP
CB
F stim
/ C
BF b
asal
1.0
1.2
1.4
1.6
PAV/PAVAVI/AVI
2 min
50%2 hrs PAO1
CPBS
ATP
CB
F stim
/ C
BF b
asal
1.0
1.2
1.4
1.6
1.8
PAV/PAVAVI/AVI
50% dialyzed 6 hrs PAO1
CPBS
ATP
2 minCB
F stim
/ C
BF b
asal
1.0
1.2
1.4
1.6
PAV/PAVAVI/AVI
2 min
50%6 hrs PAO1
CPBS
ATP
CB
F stim
/ C
BF b
asal
1.0
1.2
1.4
1.6
1.8
PAV/PAVAVI/AVI
50% 6 hrs PAO-JP2 CPBS
ATP
2 minCB
F stim
/ C
BF b
asal
1.0
1.2
1.4
1.6
1.8
PAV/PAVAVI/AVI
2 min
50% 6 hrs Sad36 CPBS
ATP
CB
F stim
/ C
BF b
asal
Supplementary Figure 18
BA C
D E F
Supplementary Material “Genetics of the bitter taste receptor T2R38 underlie susceptibility to upper respiratory infection”
19
Supplementary Figure 19 C4HSL-activated CBF increase is blocked by inhibition of NOS. (A) In PAV/PAV cultures in the presence of D-NAME (n = 8 cultures from 4 patients), peak C4HSL-stimulated CBF was 1.19 ± 0.05. In the presence of L-NAME (middle panel; n = 6 cultures from 3 patients), the peak CBF was reduced to 1.01 ± 0.02 (P <0.05 vs D-NAME by Student’s t-test). (B) Bar graph of data from A taking the peaks from each experiment then averaging results from each patient (3-4 each; * = P <0.05). In response to C4HSL, peak CBF was 1.03 ± 0.02 (PAV/PAV + L-NAME; P <0.05 vs PAV/PAV without L-NAME [Figure 4E] by ANOVA), and 1.19 ± 0.02 (PAV/PAV + D-NAME; n.s. vs PAV/PAV control [Figure 4E] and P <0.05 vs PAV/PAV + L-NAME by ANOVA). In response to ATP-stimulation, peak CBF increase was 1.57 ± 0.08 (PAV/PAV + L-NAME) and 1.73 ± 0.11 (PAV/PAV + D-NAME; n.s. compared with each other or with values in Figure 4E by ANOVA).
1.0
1.5
2.0
5 min
C4HSL
10 !M ATP
CB
Fstim
/ C
BF
basal
PAV/PAV + L-NAMEPAV/PAV + D-NAME
C4HSL ATP1.0
1.1
1.2
1.41.61.82.0
CB
Fstim
/ C
BF
basal
*
n.s.
PAV/PAV + L-NAME
PAV/PAV + D-NAME
A
B
Supplementary Figure 19
Supplementary Material “Genetics of the bitter taste receptor T2R38 underlie susceptibility to upper respiratory infection”
20
Supplementary Figure 20 Conditioned medium (CM)-stimulated and C4HSL-stimulated CBF increases were blocked by inhibitors of cGMP/PKG signaling. (A) Average trace of normalized CBF in PAV/PAV cultures stimulated with 6.25% CM in the presence of the PKG inhibitor KT5823 (2 µM; n = 6 cultures from 3 patients). (B) Average trace of CBF during C4HSL (200 µM) stimulation in the presence of KT5823 (n = 6 cultures from 3 patients). (C) Average trace of CBF during stimulation with C4HSL in the presence of the soluble guanylyl cyclase inhibitor LY83583 (50 µM; n = 5 cultures from 2 pts). (D) Average trace of CBF during stimulation with C4HSL in the presence of the PKG inhibitor H8 (5 µM; n = 6 cultures from 3 pts).
0.8
1.0
1.2
1.4
1.6
1.8
CB
Fstim
/ C
BF
basal
PAV/PAV + C4HSL + KT5823
2 min
C4HSL
ATP
0.8
1.0
1.2
1.4
1.6
1.8
CB
Fstim
/ C
BF
basal
2 min
CM
ATP
PAV/PAV + 6.25% CM + KT5823
0.8
1.0
1.2
1.4
1.6
1.8
CB
Fstim
/ C
BF
basal
2 min
C4HSL
ATP
PAV/PAV + C4HSL + LY83583 0.8
1.0
1.2
1.4
1.6
1.8
CB
Fstim
/ C
BF
basal
2 min
C4HSL
ATP
PAV/PAV + C4HSL + H8
A B
C D
Supplementary Figure 20
Supplementary Material “Genetics of the bitter taste receptor T2R38 underlie susceptibility to upper respiratory infection”
21
Supplementary Figure 21 Validation of Live/Dead staining technique. (A-B) Pseudomonas (PAO1) were incubated on transwell filters (no human cells) as described in the text in either saline (A) or saline + colistin (B). Saline-exposed bacteria exhibited nearly universal green fluorescence while colistin-exposed bacteria exhibited nearly universal red fluorescence. As demonstrated by the images, signal bleed-through was minimal between red and green channels. Quantification of staining is presented in the Figure 7.
A BsalinePAO1
colistinPAO1
Green(Syto9)
Red(PI)
Merge
Supplementary Figure 21
Supplementary Material “Genetics of the bitter taste receptor T2R38 underlie susceptibility to upper respiratory infection”
22
Supplementary Figure 22 T2R38-dependent antibacterial activity is dependent upon NO and HSLs; (A-B) Inhibition of NOS using L-NAME (applied to the basolateral side) or NO scavenging with cPTIO (applied to the apical side along with the bacteria) increased the number of viable (green) PAO1, suggesting NO is required for maximal bacterial killing. (C) Minimal killing was observed with HSL-deficient PAO-JP2. However, addition of 10 µM C4HSL and 10 µM C12HSL when PAO-JP2 was added to the cultures resulted in near-complete killing in PAV/PAV but not AVI/AVI cultures. Quantification of staining is presented in the Figure 7.
PAV/PAVPAO-JP2
AVI/AVIPAO-JP2
AVI/AVIPAO-JP2+C4/C12HSL
C PAV/PAVPAO-JP2+C4/C12HSL
Green(Syto9)
Red(PI)
Merge
A B
Green(Syto9)
Red(PI)
Merge
PAV/PAV+ cPTIOPAO1
PAV/PAV+ L-NAMEPAO1
Supplementary Figure 22
Supplementary Material “Genetics of the bitter taste receptor T2R38 underlie susceptibility to upper respiratory infection”
23
Supplementary Table 1 Microbiology reports and patient information. Genotypes of 4 T2Rs (38, 19, 46, and 30) and correlated microbiology reports from patients utilized in Table 1. Additionally, patient sex, age, site of tissue acquisition, indication for surgery, number of prior sinus surgeries, presence of sinonasal polyps and medications used at least one month prior to surgery. In the “no growth” group there were 35 patients of whom 66% were male, average age was 47.5 years with a range of 24 - 78 years. These patients on average had 1.1 prior sinonasal procedures and 51% had sinonasal polyps. In those patients with positive cultures for gram-negative bacteria, there were 21 patients of whom 38% were male, average age was 47.9 years with a range of 21-79. In this group, patients had on average 1.9 prior sinonasal procedures (p=0.059) and 57% had sinonasal polyps. [CNV = putative copy number variants, FESS = functional endoscopic sinus surgery, CRS = chronic rhinosinusitis, PT = pituitary tumor, TH = inferior turbinate hypertrophy]
Microbiology Report
T2R38
Genotype
TAS2R19
rs10772420
TAS2R46
rs2708381
TAS2R30
rs2599404 Gender Age Site
Indication for surgery
# Prior FESS Polyps Co-Morbids Prior Medical Management
No Growth
1 Rare Staphylococcus species (Coagulase Negative) AVI/PAV A/G C/T A/C F 61 Ethmoid CRS 0 No Asthma, AR, GERD, HTN, DM Amoxicillin/Clavulanic acid, Nasal steroids, saline irrigations2 Few Mixed Upper Respiratory Flora AVI/PAV A/G C/C A/C M 51 Ethmoid CRS 3 Yes Asthma, AR, GERD, ASA intolerance Levofloxacin, Prednisone, Nasal steroids, saline irrigations3 No Growth AVI/PAV G/G C/C A/A F 72 Ethmoid CRS 1 No None Ciprofloxacin, Nasal steroids, saline irrigations4 Few Staphylococcus species (Coagulase Negative) AVI/PAV A/A M 64 Sphenoid PT 0 No AR, HTN Nasal steroids5 Few Staphylococcus species (Coagulase Negative) AVI/PAV A/G C/C A/C F 24 Ethmoid CRS 0 No Asthma, AR Minocycline, Nasal steroids, saline irrigations6 Moderate Staphylococcus species (Coagulase Negative) AVI/PAV C/T A/C M 44 Ethmoid CRS 0 Yes AR, GERD Nasal steroids, saline irrigations7 Few Staphylococcus species (Coagulase Negative) AVI/PAV T/T C/C M 25 Ethmoid CRS 0 No AR, HTN, DM Clindamycin, Prednisone, saline irrigations8 Moderate Staphylococcus species (Coagulase Negative) AVI/PAV M 37 Ethmoid CRS 4 Yes Asthma, AR, GERD Prednisone, Nasal steroids, saline irrigations9 Few Staphylococcus species (Coagulase Negative) AVI/PAV C/C M 54 Ethmoid CRS 2 Yes Asthma, ASA intolerance Nasal steroids, saline irrigations10 No Growth AVI/PAV C/C CNV F 46 turbinate TH 0 No non-allergic rhinitis Nasal steroids, ipratropium bromide, saline irrigations11 No Growth AVI/PAV M 39 turbinate TH 0 No non-allergic rhinitis Nasal steroids, ipratropium bromide, saline irrigations12 No Growth AVI/AVI A/G C/C A/C F 29 Ethmoid CRS 0 No AR Levofloxacin, Prednisone, saline irrigations13 Few Mixed Upper Respiratory Flora AVI/AVI A/A C/T C/C M 38 Ethmoid CRS 3 Yes Hx of Polyps Prednisone, Nasal steroids, saline irrigations14 Few Mixed Upper Respiratory Flora AVI/AVI A/G C/T A/C F 41 Ethmoid CRS 1 Yes AR, GERD Prednisone,Nasal steroids, saline irrigations15 No Growth AVI/AVI A/G C/C A/C M 33 Ethmoid CRS 0 Yes AR Cirprofloxacin, Prednisone, Nasal steroids, saline irrigations16 Few Staphylococcus species (Coagulase Negative) AVI/AVI A/G C/T A/C M 56 Ethmoid CRS 1 Yes AR, HTN Prednisone, Nasal steroids, saline irrigations17 Few Staphylococcus species (Coagulase Negative) AVI/AVI A/G C/C A/C M 51 Ethmoid CRS 0 No Asthma, AR Nasal steroids, saline irrigations18 Few Mixed Upper Respiratory Flora AVI/AVI A/G C/T A/C M 41 Sphenoid PT 0 No None None19 Few Staphylococcus species (Coagulase Negative) AVI/AVI A/G C/T A/C F 75 Ethmoid CRS 5 Yes Asthma, ASA intolerance,, AR Prednisone, Nasal steroids, saline irrigations20 Few Staphylococcus species (Coagulase Negative) AVI/AVI A/G C/C A/C F 25 Ethmoid CRS 4 Yes GERD, HTN Ciprofloxacin, Prednisone, Nasal steroids, Bactroban nasal irrigations21 Few Staphylococcus species (Coagulase Negative) AVI/AVI C/C A/C M 57 Ethmoid CRS 1 Yes AR, GERD, HTN Prednisone,Nasal steroids, saline irrigations22 Few Staphylococcus species (Coagulase Negative) AVI/AVI C/T C/C F 56 Sphenoid PT 0 No HTN, DM None23 Rare Staphylococcus species (Coagulase Negative) AVI/AVI C/T A/C F 36 Ethmoid CRS 0 Yes Asthma, AR Nasal steroids, saline irrigations24 No Growth AVI/AVI M 31 turbinate TH 0 No non-allergic rhinitis, HTN Nasal steroids, saline irrigations25 No Growth PAV/PAV G/G C/C A/A M 39 Sphenoid PT 0 No AR, GERD None26 No Growth PAV/PAV A/G C/T A/C F 38 Ethmoid CRS 2 Yes AR Nasal steroids, saline irrigations27 Few Staphylococcus species (Coagulase Negative) PAV/PAV A/G C/C A/C M 59 Ethmoid CRS 1 No None Levofloxacin, Prednisone, Nasal steroids, saline irrigations28 No Growth PAV/PAV G/G C/C A/A F 34 Ethmoid CRS 2 Yes Asthma Levofloxacin, Prednisone, Nasal steroids, saline irrigations29 Few Staphylococcus species (Coagulase Negative) PAV/PAV M 78 Frontals CRS 1 No AR, HTN, GERD, DM Nasal steroids, saline irrigations30 No Growth PAV/PAV A/A C/T C/C M 42 Ethmoid CRS 3 Yes Asthma, AR, GERD Levofloxacin, prednisone, Nasal steroids, saline irrigations31 Moderate Mixed Upper Respiratory Flora PAV/PAV C/T A/C M 44 Sphenoid PT 0 No GERD None32 No Growth PAV/PAV A/A T/T C/C M 75 Ethmoid CRS 2 Yes AR Prednisone, Nasal steroids, saline irrigations33 Few Mixed Upper Respiratory Flora PAV/PAV T/T C/C M 64 Ethmoid CRS 1 Yes None Prednisone, Nasal steroids, saline irrigations34 Few Staphylococcus species (Coagulase Negative) PAV/PAV C/C A/A M 36 Ethmoid CRS 2 Yes Asthma, AR, GERD, DM Prednisone, Nasal steroids, saline irrigations35 Few Staphylococcus species (Coagulase Negative) PAV/PAV C/C A/C M 66 ethmoid CRS 0 No None Amoxicillin/Clavulanic acid, Prednisone, Nasal steroids, saline irrigations
Gram Negative
36 Moderate Pseudomonas aeruginosa; Few Staphylococcus species (Coagulase Negative)
AVI/PAV A/A C/T C/C M 50 Ethmoid CRS 3 No Asthma, AR Clindamycin, Prednisone, Nasal steroids, saline irrigations
37 Moderate Pseudomonas aeruginosa; Few Escherichia coli
AVI/PAV A/A C/T C/C M 54 Ethmoid CRS 6 Yes Asthma, AR Levofloxacin, Pulmicort irrigations
38 Moderate Serratia marcescens; Few Haemophilus influenzae; Rare Mixed Upper Respiratory Flora
AVI/PAV G/G C/C A/A F 45 Ethmoid CRS 3 Yes Asthma, AR Prednisone, Nasal steroids, saline irrigations
39 Many Pseudomonas aeruginosa AVI/PAV A/G C/T A/C F 65 Ethmoid CRS 1 No GERD Amoxicillin/Clavulanic acid, Nasal steroids, saline irrigations40 Many Pseudomonas aeruginosa, Non-Mucoid Strain;
Moderate Pseudomonas aeruginosa, Mucoid Strain; Moderate Staphylococcus species (Coagulase Negative)
AVI/PAV A/G C/C A/C F 64 Ethmoid CRS 2 No HTN, DM Levofloxcin, Prednisone, Nasal steroids, saline irrigations
41 Pseudomonas aeruginosa AVI/PAV A/A C/C C/C F 45 Maxillary CRS 0 No None Amoxicillin/Clavulanic acid, Prednisone, Nasal steroids, saline irrigations42 Few Pseudomonas aeruginosa AVI/PAV G/G C/C A/A M 53 Ethmoid CRS 1 Yes GERD, HTN Prednisone, Nasal steroids, saline irrigations43 Many Pseudomonas aeruginosa AVI/PAV A/A C/C C/C M 34 Ethmoid CRS 0 No AR, GERD Prednisone, Nasal steroids, saline irrigations44 Few Moraxella catarrhalis; Rare Staphylococcus aureus;
Rare Streptococcus pneumoniae; Few Staphylococcus species (Coagulase Negative)
AVI/PAV G/G C/C A/A M 35 Ethmoid CRS 2 Yes Asthma, AR, GERD Prednisone, Nasal steroids, saline irrigations
45 Moderate Pseudomonas aeruginosa; Moderate Staphylococcus aureus
AVI/PAV CNV A/C F 21 Ethmoid CRS 0 Yes None Nasal steroids, saline irrigations
46 Moderate Enterobacter aerogenes; Escherichia coli; Few Staphylococcus species (Coagulase Negative)
AVI/PAV A/G C/T A/C M 70 Ethmoid CRS 0 No Asthma Prednisone, Nasal steroids, saline irrigations
47 Moderate Pseudomonas aeruginosa; Moderate Staphylococcus aureus; Moderate Streptococcus agalactiae (Group B)
AVI/PAV A/G C/C A/C F 44 Ethmoid CRS 2 No AR, GERD Nasal steroids, saline irrigations
48 Few Citrobacter koseri AVI/PAV F 52 Ethmoid CRS 2 Yes Asthma Nasal steroids, saline irrigations49 Many Enterobacter aerogenes AVI/PAV G/G C/C A/A F 35 Ethmoid CRS 3 Yes Asthma, ASA intolerance, AR Prednisone, Nasal steroids, saline irrigations50 Many Pseudomonas aeruginosa AVI/AVI F 63 Ethmoid CRS 5 No None Moxifloxacin, Prednisone, Nasal steroids, saline irrigations51 Many Pseudomonas aeruginosa AVI/AVI A/G C/T A/C F 45 Ethmoid CRS 5 Yes Asthma, AR, GERD Ciprofloxacin, Prednisone, Nasal steroids, saline irrigations52 Moderate Pseudomonas aeruginosa, Mucoid Strain; Few
Staphylococcus species (Coagulase Negative)AVI/AVI G/G C/C A/A F 29 Ethmoid CRS 2 Yes AR Prednisone, Nasal steroids, saline irrigations
53 Moderate Pseudomonas aeruginosa, Mucoid Strain; Moderate Achromobacter denitrificans;
AVI/AVI A/A C/T C/C F 38 Ethmoid CRS 2 Yes Asthma, ASA intolerance, AR, GERD Amoxicillin/Clavulanic acid, Prednisone, Nasal steroids, saline irrigations
54 Many Methicillin-Resistant Staphylococcus aureus; Moderate Pseudomonas aeruginosa; Few Morganella morganii ssp. morganii
AVI/AVI G/G C/C A/A M 59 Ethmoid CRS 0 Yes Asthma, AR, GERD Nasal steroids, saline irrigations
55 Many Pseudomonas aeruginosa AVI/AVI C/C A/C F 46 Ethmoid CRS 0 Yes Asthma, AR, GERD, HTN Prednisone, Nasal steroids, saline irrigations 56 Moderate Serratia marcescens; Few Staphylococcus
species (Coagulase Negative) AVI/AVI M 58 Ethmoid CRS 0 No Asthma, AR, GERD Clindamycin, Prednisone, Nasal steroids, saline irrigations
Supplementary Material “Genetics of the bitter taste receptor T2R38 underlie susceptibility to upper respiratory infection”
24
REFERENCE 1. Palmer, R.K., Atwal, K., Bakaj, I., Carlucci-Derbyshire, S., Buber, M.T., Cerne, R., Cortes, R.Y., Devantier, H.R.,
Jorgensen, V., Pawlyk, A., et al. 2010. Triphenylphosphine oxide is a potent and selective inhibitor of the transient receptor potential melastatin-5 ion channel. Assay Drug Dev Technol 8:703-713.